Influenza Challenge Study of VIS410 in Healthy Volunteers

Summary

A phase 2 a study to assess the safety profile and the effect of VIS410 in healthy subjects after inoculation with influenza A virus (H1N1).

Timeline

Start

2015-05

Primary completion

2016-02

Completion

2016-02

Outcome

Met primary endpoint

paper VIS410 treatment was associated with a 76% reduction in median VL AUC as measured by qRT-PCR (p = 0.024). PMID 32151645 ↗

Publications

• Sloan SE, Szretter KJ, Sundaresh B, Narayan KM, Smith PF, Skurnik D, Bedard S, Trevejo JM, Oldach D, Shriver Z. Clinical and virological responses to a broad-spectrum human monoclonal antibody in an influenza virus challenge study. Antiviral Res. 2020 Dec;184:104763. doi: 10.1016/j.antiviral.2020.104763. Epub 2020 Mar 7.

Drugs

Indications